Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma

Status unconfirmed · Phase 1

Conditions studied: Malignant Mesothelioma

In brief

RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus ganciclovir in treating patients who have stage I, stage II, or stage III malignant mesothelioma.

Key facts

Study ID

NCT00006216

Run by

Louisiana State University Health Sciences Center in New Orleans

Starts

1997-08-01

Last updated by the study team

2013-09-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Louisiana State University School of Medicine — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.